KROS
Keros Therapeutics, Inc. (KROS) Porter's 5 Forces Analysis (2026)
Overall Score
Threat Of New Entrants
High cash balance and very strong current ratio (21.96x) support resilience, but the company’s small market cap keeps it vulnerable to new competitive pressure.
Low debt-to-equity (0.06x) and modest enterprise value relative to sales suggest a limited financial moat rather than a strong barrier to entry.
Bargaining Power Of Suppliers
No inventory and a negative cash conversion cycle indicate working-capital efficiency, but the very high days payable outstanding (830.6) suggests supplier terms are already stretched.
Heavy R&D and SG&A intensity imply dependence on specialized inputs and talent, which can preserve some supplier leverage.
Bargaining Power Of Buyers
Gross margin remains very high at 94.7%, indicating some pricing power, but the company’s small scale limits its ability to dictate terms broadly.
Weak profitability and negative operating margins suggest customers can still pressure pricing if product differentiation is not sustained.
Threat Of Substitutes
The business appears differentiated enough to maintain a high gross margin, but the lack of positive earnings or cash flow makes it harder to defend against alternative solutions.
Low asset turnover and negative returns on capital indicate the offering has not yet translated into durable economic advantage versus substitutes.
Industry Competition
Negative operating margin (-6.8%) and negative ROIC (-35.2%) point to a competitive environment where value capture remains weak.
Strong liquidity and low leverage reduce near-term distress risk, but they do not eliminate competitive pressure in a small-cap, innovation-driven market.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Keros Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

